CBC

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024

Retrieved on: 
星期五, 五月 10, 2024
Inflammation, RNA, UC, Hepatology, Patient, Northwestern University, CBC, Associate, Division

Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY

Key Points: 
  • Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY
    Obefazimod and its active metabolites ABX-464-N-Glu act by stabilizing protein-protein interaction among key RNA biogenesis partners, CBC and ARS2
    Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose
    Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY
    Abivax has also sponsored a Product Theater presentation titled, “ An Investigational New MOA that Can Stabilize the Inflammatory Response in Ulcerative Colitis ,” taking place on May 20, 2024, at 2:30-3:15 p.m. EDT in room “DDW Theater 1,” featuring Prof. Parambir S. Dulai, M.D., Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois, U.S.

Cronos Group Reports 2024 First Quarter Results

Retrieved on: 
星期四, 五月 9, 2024
Cream, Mazor Robotics, Genetics, Certified Public Accountant, Wedding cake, Investment, Fully Charged, Average cost, Capital, EY, Pharma, Depreciation, Cannabinol, Flower, Robotics, Traction, GMO, Partnership, Research, Capital expenditure, Medtronic, Tax, Senior, Patient, Vii, Hamas, CBC, Motus, CBN, Lord, CBG, Growth, Drug

TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announces its 2024 first quarter business results.

Key Points: 
  • Cronos Growing Company Inc. ("Cronos GrowCo") reported to the Company preliminary unaudited net revenue to licensed producers, excluding sales to the Company, of approximately $5.1 million in the first quarter of 2024.
  • Cronos previously provided Cronos GrowCo with a senior secured credit facility, which currently has approximately $67.1 million outstanding following a principal repayment of $1.2 million by Cronos GrowCo in Q1 2024.
  • In addition to principal repayment, Cronos also received $1.4 million in interest payments from Cronos GrowCo, totaling approximately $2.7 million in cash payments to Cronos in Q1 2024.
  • Before becoming Head of Cronos Israel, he was the Vice President of Finance at Cronos Israel managing the Cronos Israel finance department.

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024

Retrieved on: 
星期三, 五月 8, 2024
Inflammation, RNA, UC, Hepatology, Patient, Northwestern University, CBC, Associate, Division

Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY

Key Points: 
  • Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY
    Obefazimod and its active metabolites ABX-464-N-Glu act by stabilizing protein-protein interaction among key RNA biogenesis partners, CBC and ARS2
    Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose
    Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY
    Abivax has also sponsored a Product Theater presentation titled, “ An Investigational New MOA that Can Stabilize the Inflammatory Response in Ulcerative Colitis ,” taking place on May 20, 2024, at 2:30-3:15 p.m. EDT in room “DDW Theater 1,” featuring Prof. Parambir S. Dulai, M.D., Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois, U.S.

Beckman Coulter and MeMed Extend Partnership Advancing Host Immune Response Diagnostics

Retrieved on: 
星期二, 五月 7, 2024
Ambiguity, BV, Genetically modified bacteria, TRAIL, Risk, Infection, Procalcitonin, Sepsis, CRP, Septic shock, Partnership, Research, NPV, PCT, Patient, Microbiology, Physician, Ministry, Serum, MDW, Beckman Coulter, CBC, Risk assessment, Viral, US FDA, Vaccine

BREA, Calif. and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, today announced expansion of their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed BV® assay, a rapid immunoassay test able to distinguish between bacterial and viral infections, and MeMed Key®, a compact immunoassay analyzer cleared to run the MeMed BV assay in the United States and Europe. This new distribution agreement complements the existing joint effort to develop a MeMed BV-based test for Beckman Coulter's family of Access Immunoassay Analyzers.

Key Points: 
  • BREA, Calif. and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, today announced expansion of their host immune response diagnostics partnership.
  • Beckman Coulter is now an authorized distributor of the MeMed BV® assay , a rapid immunoassay test able to distinguish between bacterial and viral infections, and MeMed Key® , a compact immunoassay analyzer cleared to run the MeMed BV assay in the United States and Europe.
  • This new distribution agreement complements the existing joint effort to develop a MeMed BV-based test for Beckman Coulter's family of Access Immunoassay Analyzers .
  • "To that end, we are excited to extend our partnership with MeMed by expanding market access to the MeMed Key and BV assay.

RSA Conference 2024 Opens in San Francisco

Retrieved on: 
星期一, 五月 6, 2024
Cloud, BigID, Fortinet, BlackBerry, ICSF, OneTrust, Community, Tufin, CBC, RSA, TeleTrusT, OpenText, GitLab, SentinelOne, RSA Conference, IBM, Conference, Sophos, Faculty, Check Point, Workforce, CLF, Verizon Business, SAN, LogRhythm, CrowdStrike, Cisco, ESAF, LastPass, Student, Government, Jay Westerdal, SonicWall, Moscone Center, ExtraHop Networks, AT&T Cybersecurity, University, Senior, BitSight, Okta, Rubrik, RSAC, SecurityScorecard

SAN FRANCISCO, May 6, 2024 /PRNewswire/ -- RSA Conference™, the world's leading cybersecurity conferences and expositions, opens its annual event today in San Francisco.

Key Points: 
  • SAN FRANCISCO, May 6, 2024 /PRNewswire/ -- RSA Conference™, the world's leading cybersecurity conferences and expositions, opens its annual event today in San Francisco.
  • "Community is at our core and the excitement surrounding what we have in store at RSA Conference this week is palpable.
  • RSA Conference 2024 will feature eight uniquely different sandboxes, an escape room, and dozens of interactive experiences.
  • For more information regarding RSA Conference 2024, taking place at the Moscone Center in San Francisco this week, visit our website at www.rsaconference.com/usa .

Feed the Dream: Empire Company Limited inspires Canadians to cheer on Team Canada at the Paris 2024 Olympic and Paralympic Games

Retrieved on: 
星期四, 五月 2, 2024
Beach volleyball, COC, Canadian Olympic Committee, Perseverance, Sport, Game, IGA, Dream, Marketing, TSX, Partnership, House, Thrifty Foods, Friends, Canadian Paralympic Committee, Family, Olympic Games, Empire Company, Food, Athlete, Safeway, NS, Canada national team, CBC, The Company

'Feed the Dream' celebrates the friends, families, and hometowns who nourish the hearts and dreams of Team Canada

Key Points: 
  • 'Feed the Dream' celebrates the friends, families, and hometowns who nourish the hearts and dreams of Team Canada
    STELLARTON, NS, May 2, 2024 /CNW/ - Today, Empire Company Limited ("Empire" or the "Company") (TSX: EMP.A), the Official Grocer of Team Canada, is proud to launch its Feed the Dream campaign to celebrate the Paris 2024 Olympic and Paralympic Games.
  • The Feed the Dream lunchbox is a unique way to remind Team Canada that their friends, families, hometown communities, and country are all cheering them on.
  • Empire is committed to connect families and communities through food as they watch, cheer, and support Team Canada this summer.
  • Canadians can learn more about Feed the Dream, participate in contests and giveaways and show their support for Team Sobeys athletes by leaving encouraging messages at www.FeedTheDream.ca .

CJF Black Journalism Fellows Announced

Retrieved on: 
星期三, 五月 1, 2024
University, Grant, Bank of Montreal, MacEwan University, News, Mentorship, Public health, Partnership, Research, IJB, CTV News, Canadian Journalism Foundation, CTV, Humanities, Fairmont Royal York, Communication, Newsroom, Cision, CJF, Journalism, BMO, Special creation, Canadian Broadcasting Corporation, Carleton University, National Post, CBC, Canada Life, Aritzia, Bell Media, Toronto Star, Medical device

The fellowship program aims to amplify Black voices, improve coverage of Black issues in the news and cultivate future Black media leaders.

Key Points: 
  • The fellowship program aims to amplify Black voices, improve coverage of Black issues in the news and cultivate future Black media leaders.
  • Dominique Gené, a freelance journalist and 2024 Journalism and Humanities graduate of Carleton University, recipient of the CJF-Globe and Mail Black Business Journalism Fellowship;
    Démar Grant, a freelance journalist from Mississauga, ON., recipient of the CJF-IJB Black Journalism Fellowship;
    Zuhra Jibril, a freelance journalist and Master's student at the Carleton University School of Journalism and Communication, recipient of the CJF-CTV News Black Journalism Fellowship;
    Daysha Loppie, a freelance journalist from Toronto, recipient of the CJF-CBC/Radio-Canada Black Women's Journalism Fellowship; and
    Aajah Sauter, a student journalist at Grant MacEwan University, recipient of the CJF-CBC/Radio-Canada Black Journalism Fellowship.
  • "This year's CJF Black Journalism Fellows will bring great energy and fresh perspectives to Canadian newsrooms," says jury member Melissa Stasiuk, Head of Newsroom Development at The Globe and Mail.
  • Thanks to the generous support of our sponsors:
    Aritzia: CJF-CBC/Radio-Canada Black Women's Journalism Fellowship;
    BMO Financial Group: CJF-CTV News Black Journalism Fellowship;
    Canada Life: CJF-Globe and Mail Black Business Journalism Fellowship;
    Unifor and North Horizon: CJF-IJB Black Investigative Journalism Fellowship.

EFA Technologies, pioneer in portable blood labs, enters Brazilian market after Anvisa approval of its portable RevDx device

Retrieved on: 
星期三, 四月 10, 2024
Medtech, ARC, Blood, Certification, Brazilian Health Regulatory Agency, EFA, Patient, ANVISA, Caregiver, Health, Biomarker, CBC, CE

RevDx , EFA’s flagship product, is a sophisticated portable diagnostic device that leverages advanced technology to provide accurate and rapid medical testing locally.

Key Points: 
  • RevDx , EFA’s flagship product, is a sophisticated portable diagnostic device that leverages advanced technology to provide accurate and rapid medical testing locally.
  • Our mission to make Medtech accessible to everybody, starting with a complete blood count test (CBC), is coming to fruition.
  • EFA Technologies has obtained CE certification and enters the Brazilian market with ANVISA certification for RevDx.
  • RevDx , is a sophisticated portable diagnostic device that leverages advanced technology to provide accurate and rapid medical testing locally.

ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management

Retrieved on: 
星期二, 四月 23, 2024
Biotechnology, Pharmaceutical, Alternative Medicine, Managed Care, Health, FDA, Clinical Trials, Other Health, Patent Cooperation Treaty, Pain, PAIN, Clinical trial, Safety, THC, Research, CBD, Patent, Pain management, Patient, Medicine, Cannabinoid, Cannabidiol, CBC, Chronic pain, Investigational New Drug, Pharmaceutical industry

ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, announced today that the USPTO issued U.S. Patent No.

Key Points: 
  • ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, announced today that the USPTO issued U.S. Patent No.
  • The patent, held by ZYUS’ wholly owned subsidiary, ZYUS Life Sciences Inc., is based on International Patent Application No.
  • This marks the seventh issuance of a patent in this patent family, joining other jurisdictions such as Canada, Australia, Israel, India, Korea and South Africa.
  • ZYUS’ intellectual property portfolio contains multiple patent families related to fixed-dose cannabinoid-based formulations for the treatment of pain and a variety of other clinically unmet needs.

Stop subsidizing Drax's forest destruction, environmental injustices, and climate damage, say Dogwood Alliance and other environmental groups

Retrieved on: 
星期四, 四月 25, 2024
Carbon, Dogwood Alliance, Climate change, Burns, BBC, BECCS, Climate, Health, Electricity, Government, Growth, Plant, Environment, Tree, Urinary tract infection, Noise, Wood, Soil, CBC, Annual report, Atmosphere, Asthma, NAACP, Southern United States, Air pollution

 WASHINGTON, April 25, 2024 /PRNewswire/ -- As Drax stakeholders gather for the giant biomass company's annual general meeting on April 25 in London, community leaders, scientists, and activists on both sides of the Atlantic are calling for an end to the logging, wood-pellet making, and burning that is harming communities and forests in the U.S. and Canada, polluting the air in Europe and Asia, and contributing to climate change that affects the entire planet.

Key Points: 
  • "We want both the U.S. and the U.K. to hear our pleas to stop burning wood for energy.
  • "With its global reach and continuing drive for government support, Drax is becoming one of the world's most dangerous forest destroyers.
  • And still, the company tries to frame its efforts as climate-friendly and good for the environment," said Adam Colette of Dogwood Alliance.
  • Drax is betting big on an expensive and largely unproven technology called Bioenergy with Carbon Capture and Storage, or BECCS.